Rwanda Achieves Key Milestone in Medical Regulation Excellence

Rwanda has been officially recognized by the World Health Organization (WHO) as having reached Maturity Level 3 (ML3) in the global classification of national regulatory authorities. This achievement highlights the country’s dedication to ensuring safe, effective, and high-quality medical products for its population. The Rwanda Food and Drugs Authority (FDA) attained ML3 following an extensive assessment completed in October 2024, conducted in collaboration with the WHO Regional Office for Africa (AFRO) and the WHO country office in Rwanda. This milestone positions Rwanda among only eight Afr

Rwanda has been officially recognized by the World Health Organization (WHO) as having reached Maturity Level 3 (ML3) in the global classification of national regulatory authorities. This achievement highlights the country’s dedication to ensuring safe, effective, and high-quality medical products for its population. The Rwanda Food and Drugs Authority (FDA) attained ML3 following an extensive assessment completed in October 2024, conducted in collaboration with the WHO Regional Office for Africa (AFRO) and the WHO country office in Rwanda. This milestone positions Rwanda among only eight African nations to achieve ML3 status, joining Egypt, Ghana, Nigeria, Senegal, South Africa, Tanzania, and Zimbabwe. Reaching ML3 signifies that Rwanda's regulatory system is stable, well-functioning, and integrated, capable of efficiently authorizing medical products and ensuring rigorous safety monitoring. Dr. Yukiko Nakatani, WHO Assistant Director-General, praised Rwanda's accomplishment as a crucial step for the East African region. This recognition reinforces Rwanda’s commitment to healthcare excellence and contributes to the broader goal of strengthening Africa’s regulatory landscape, paving the way for improved health outcomes for its citizens.